Cite
The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
MLA
Kucuk, Ahmet, et al. “The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.” Journal of Oncology, Dec. 2020, pp. 1–8. EBSCOhost, https://doi.org/10.1155/2020/8832145.
APA
Kucuk, A., Ozkan, E. E., Eskici Oztep, S., Mertsoylu, H., Pehlivan, B., Selek, U., & Topkan, E. (2020). The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy. Journal of Oncology, 1–8. https://doi.org/10.1155/2020/8832145
Chicago
Kucuk, Ahmet, Emine Elif Ozkan, Sukran Eskici Oztep, Huseyin Mertsoylu, Berrin Pehlivan, Ugur Selek, and Erkan Topkan. 2020. “The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.” Journal of Oncology, December, 1–8. doi:10.1155/2020/8832145.